Global Idiopathic Thrombocytopenic Purpura Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

Description

List of Tables

The global demand for Idiopathic Thrombocytopenic Purpura Therapeutics Market is presumed to reach the market size of nearly USD 1347.54 MN by 2030 from USD 700.59 MN in 2022 with a CAGR of 8.52% under the study period 2023 - 2030.

Idiopathic thrombocytopenic purpura or ITP is an autoimmune disorder that leads to a low platelet count in the blood. Platelets are necessary for proper blood clotting, and its low count can cause excessive bleeding and bruising. ITP therapeutics refers to the drugs, treatments, and medical devices used to manage and treat idiopathic thrombocytopenic purpura

Market Dynamics:

The prevalence of ITP is increasing globally due to factors such as ageing populations and a rise in autoimmune disorders. This is driving demand for ITP therapeutics market. Technological advancements in ITP therapeutics, such as the development of biological drugs, are improving treatment outcomes and driving the market growth. Governments around the world are providing financial support and incentives to promote the development and adoption of ITP therapeutics, driving the market growth. Increasing awareness about ITP and its treatment options is driving demand for ITP therapeutics as more individuals seek out effective treatment options. Despite the availability of some treatments, there is still a high unmet need for more effective and affordable ITP therapeutics, driving demand for new and improved treatments. The growing market for biologics, including monoclonal antibodies and other biologic drugs, is expected to drive the growth of the ITP therapeutics market as these drugs become increasingly popular for treating ITP. Insurance companies are providing coverage for ITP therapeutics, making them more accessible and affordable for individuals with ITP, which is driving demand for these treatments.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of idiopathic thrombocytopenic purpura therapeutics. The growth and trends of idiopathic thrombocytopenic purpura therapeutics industry provide a holistic approach to this study.

Market Segmentation:

This section of the idiopathic thrombocytopenic purpura therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Corticosteroids
Intravenous Immunoglobulin
Anti-D Immunoglobulin
TPO-RA

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Idiopathic Thrombocytopenic Purpura Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the idiopathic thrombocytopenic purpura therapeutics market include Hoffman-L Roche, Amgen Inc, Grifols Biologicals Inc., and GlaxoSmithKline Plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112110446

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS MARKET ANALYSIS BY PRODUCT

6.1 Overview by Product
6.2 Historical and Forecast Data
6.3 Analysis by Product
6.4 Corticosteroids Historic and Forecast Sales by Regions
6.5 Intravenous Immunoglobulin Historic and Forecast Sales by Regions
6.6 Anti-D Immunoglobulin Historic and Forecast Sales by Regions
6.7 TPO-RA Historic and Forecast Sales by Regions

7 . GLOBAL IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS COMPANIES

8.1. Idiopathic Thrombocytopenic Purpura Therapeutics Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF IDIOPATHIC THROMBOCYTOPENIC PURPURA THERAPEUTICS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Hoffman-L Roche
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Amgen Inc
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Grifols Biologicals Inc.
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. GlaxoSmithKline Plc.
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies